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Extended-spectrum  β-lactamase (ESBL)–producing 
bacteria are emerging pathogens. To analyze risk factors for 
colonization with ESBL-producing bacteria at intensive care 
unit (ICU) admission, we conducted a prospective study of a 
3.5-year cohort of patients admitted to medical and surgical 
ICUs at the University of Maryland Medical Center. Over the 
study period, admission cultures were obtained from 5,209 
patients. Of these, 117 were colonized with ESBL-produc-
ing Escherichia coli and Klebsiella spp., and 29 (25%) had 
a subsequent ESBL-positive clinical culture. Multivariable 
analysis showed the following to be statistically associated 
with ESBL colonization at admission: piperacillin-tazobac-
tam (odds ratio [OR] 2.05, 95% conﬁ   dence interval [CI] 
1.36–3.10), vancomycin (OR 2.11, 95% CI 1.34–3.31), 
age >60 years (OR 1.79, 95% CI 1.24–2.60), and chronic 
disease score (OR 1.15; 95% CI 1.04–1.27). Coexisting 
conditions and previous antimicrobial drug exposure are 
thus predictive of colonization, and a large percentage of 
these patients have subsequent positive clinical cultures for 
ESBL-producing bacteria.
E
xtended-spectrum  β-lactamase (ESBL)–producing 
gram-negative bacteria are emerging pathogens. Clini-
cians, microbiologists, infection control practitioners, and 
hospital epidemiologists are concerned about ESBL-pro-
ducing bacteria because of the increasing incidence of such 
infections, the limitations of effective antimicrobial drug 
therapy, and adverse patient outcomes (1–5).
Research conducted to date has focused on identify-
ing risk factors for colonization with multidrug-resistant, 
gram-positive bacteria. In contrast, little research has been 
conducted to identify the risk factors for colonization with 
gram-negative multidrug-resistant bacteria in nonoutbreak 
settings. To our knowledge, no study of the magnitude of 
our study has been conducted, nor have any studies based 
in the United States sought to identify risk factors for colo-
nization with ESBL-producing bacteria on admission to an 
intensive care unit (ICU).
The primary objective of our study was to identify 
factors predictive of colonization with ESBL-producing 
bacteria at admission to an intensive care unit (ICU). In 
addition, we identiﬁ  ed the percentage of patients colonized 
with ESBL-producing bacteria who had a subsequent posi-
tive clinical culture for the same species of ESBL-produc-
ing bacteria. Understanding risk factors for colonization 
is important for several reasons. First, understanding the 
potential causal mechanisms of colonization can lead to 
successful infection control, involving antimicrobial stew-
ardship and public health interventions aimed at control-
ling the emergence of ESBL-producing bacteria. Second, 
such knowledge can help identify which patients should 
be receiving empiric ESBL-targeted antimicrobial therapy. 
Some hospitals have used active surveillance culturing for 
antimicrobial drug–resistant, gram-negative bacteria to 
help guide empiric therapy (6).
Materials and Methods
Study Population and Sample Collection
We conducted a prospective cohort study of patients 
admitted to either the surgical or medical ICU at the Uni-
versity of Maryland Medical Center from September 1, 
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2001, through June 1, 2005. Descriptions of the hospital 
and the ICUs are reported in other publications (7,8). Dur-
ing the study period, on average, 8.6 clinical cultures per 
month were positive for ESBL-producing bacteria. No 
outbreaks of ESBL-producing bacteria were found among 
clinical cultures based on control process charting. No ad-
ditional infection control precautions were used for patients 
with ESBL-producing bacteria on clinical culture. ESBL 
surveillance culture results were not given to physicians 
or nurses. Contact isolation precautions were applied for 
patients with vancomycin-resistant enterococci or methicil-
lin-resistant Staphylococcus aureus infections.
During the study period, nurses obtained perianal 
specimens for culture from all ICU patients within 48 hours 
of ICU admission. All patients who had admission culture 
results were included in this study. Patients with multiple 
admissions to either of the ICUs during the study period 
were allowed to enter the cohort of at-risk patients mul-
tiple times, as long as they were not positive for ESBL-
producing bacteria on any prior admissions (because pa-
tients remain at risk for ESBL-producing bacteria on each 
subsequent admission). This study was approved by the 
Institutional Review Board of the University of Maryland, 
Baltimore. Informed consent was not required by the In-
stitutional Review Board because perianal specimens were 
cultured as part of infection control quality improvement 
involving active surveillance culturing for vancomycin-re-
sistant enterococci.
Microbiologic Methods
The perianal cultures were processed for ESBL-pro-
ducing bacteria in real time as the specimens were collect-
ed. The perianal cultures were ﬁ  rst screened for potential 
ESBL-producing bacteria by plating onto MacConkey agar 
(Remel, Lenexa, KS, USA) with 2 μg/mL of ceftazidime 
added to the cooled agar before the plates were poured (9). 
Plates were incubated at 37°C for 24 to 48 hours. Lactose-
fermenting colonies growing on the ceftazidime-contain-
ing plates were identiﬁ  ed as Escherichia coli or Klebsiella 
species by using API 20E identiﬁ  cation strips (bioMérieux 
Vitek, Inc., Hazelwood, MO, USA). All E. coli and Klebsi-
ella isolates underwent ESBL conﬁ  rmatory testing by disk 
diffusion for ceftazidime and cefotaxime with and without 
clavulanic acid as recommended by the Clinical Laboratory 
Standards Institute’s guidelines (10).
Data Collection and Variables
For all patients included in the study, we collected 
data regarding the patient’s previous hospital antimicrobial 
drug exposures, length of hospitalization before ICU ad-
mission, coexisting conditions, previous positive cultures, 
and other hospitalization-related and demographic infor-
mation. Antimicrobial drug exposures were assessed in 
the period between hospital admission and ICU admission. 
Antimicrobial drugs were analyzed as binary variables; if 
an antimicrobial drug was received during the period de-
ﬁ  ned above, it was classiﬁ  ed as having been received in-
dependent of the number of doses received. Duration of 
antimicrobial drug exposure was not analyzed. Coexisting 
conditions were assessed by the Charlson Comorbidity In-
dex, the Chronic Disease Score (CDS), and the infectious
disease–speciﬁ  c CDS (CDS-ID) (11–13).
Initial bivariable statistical comparisons were conduct-
ed by using the χ2 test for categorical data and the Student 
t test or Wilcoxon test for continuous data. Continuous 
variables that were not normally distributed were catego-
rized for the purpose of multivariable analyses. To identify 
patient characteristics associated with colonization by an 
ESBL-producing bacterium on ICU admission, we used 
multivariable logistic regression. Because patients were 
allowed to enter into the study multiple times, we also as-
sessed the need to control for the correlated error structure 
of the data. All variables that were associated with ESBL 
colonization in the bivariable analysis at the p<0.1 level 
were included in the model-building stages of the multi-
variable analysis. A stepwise model building method was 
used. Variables were retained in the ﬁ  nal model if they 
were signiﬁ  cant at a p<0.05 level or if they were observed 
to have a confounding effect on the association between an-
other predictor and ESBL colonization status. A confound-
ing effect was deﬁ  ned as a change in the model coefﬁ  cient 
by >10%. An additional bivariable statistical analysis was 
performed to identify risk factors for subsequent clinical 
culture positivity with the same species of ESBL-produc-
ing bacteria among the cohort of patients colonized with an 
ESBL-producing bacteria. We calculated the C statistic of 
the ﬁ  nal model. The C statistic reports values from 0.5 (in-
dicating no predictive power) to 1.0 (indicating perfect pre-
diction). In addition, we calculated the sensitivity, speciﬁ  c-
ity, positive predictive value, and negative predictive value 
for patients with or without all dichotomous variables in the 
ﬁ  nal model. Statistical analysis was performed with SAS 
Version 9.1 (SAS Institute, Cary, NC, USA).
Results
During the study period, 5,209 (84%) admitted pa-
tients had results of admission perianal cultures and were 
included in this study, 4,398 patients had 1 ICU admission, 
and 618 patients had repeat admissions. Ninety-one per-
cent of the surveillance cultures were obtained within the 
ﬁ  rst 12 hours of ICU admission. The cross-sectional patient 
cohort consisted of 2,096 (40%) admissions to the medical 
ICU and 3,113 (60%) admissions to the surgical ICU. The 
mean age of the patients was 55 years. The mean comor-
bidity score as measured by the CDS–ID was 2.73 and 2.42 
as measured by the Charlson Comorbidity Index. Based RESEARCH
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upon International Classiﬁ  cation of Diseases, 9th revision 
(ICD-9) codes, 1,285 (25%) had diabetes, 1,344 (26%) had 
cancer, and 193 (4%) were HIV positive; 1,594 (31%) of 
patients had been transferred from another healthcare facil-
ity, and 1,693 (33%) had been previously admitted to the 
same hospital within the past year.
We examined patient characteristics, coexisting condi-
tions, and previous antimicrobial drug exposures to iden-
tify factors potentially associated with colonization by 
an ESBL-producing bacterium on ICU admission (Table 
1, bivariable analysis). Of 5,209 patient admissions, 117 
(2%) patients were colonized by an ESBL-producing E. 
coli or Klebsiella species bacterium on ICU admission. 
Speciﬁ   cally, 76 (65%) patients were colonized by an 
ESBL-producing E. coli, 55 (47%) were colonized by an 
ESBL-producing Klebsiella species, and 14 (12%) patients 
were colonized by both. Stratiﬁ  ed bivariable analyses by 
organism are as follows: for E. coli, zosyn (odds ratio [OR] 
1.93; 95% conﬁ  dence interval [CI] 1.17–3.18), vancomy-
cin (OR 1.66, 95% CI, 0.91–3.03), age (OR 2.51, 95% CI 
1.57–4.00), and coexisting conditions (OR 1.19, 95% CI 
1.05–1.35); for Klebsiella spp., zosyn (OR 2.30, 95% CI 
1.31–4.06), vancomycin (OR 3.91, 95% CI 2.21–6.91), age 
(OR 1.29, 95% CI 0.76–2.20), and coexisting conditions, 
as measured by CDS-ID (OR 1.12, 95% CI 0.96–1.31). 
Stratiﬁ  ed analysis results for those patients who were in 
the hospital at least 24 hours before ICU admission are as 
follows: zosyn (OR 2.34, 95% CI, 1.11–4.94), vancomycin 
(OR 3.25, 95% CI 1.57–6.75), age (OR 1.39, 95% CI 0.68–
2.86), and coexisting conditions as measured by CDS-ID 
(OR 95% CI 1.01–1.44).  
The results of the ﬁ  nal multivariable logistic regression 
analysis are shown in Table 2. Age >60 years (OR 1.79, 
95% CI 1.24–2.60), coexisting conditions as measured by 
the CDS-ID (OR 1.15, 95% CI 1.04–1.27), in-hospital use 
of piperacillin-tazobactam (OR 2.05, 95% CI 1.36–3.10), 
and in-hospital use of vancomycin (OR 2.11, 95% CI 1.34–
3.31) were all found to be independently associated with 
colonization by an ESBL-producing bacterium on admis-
sion to an ICU. No other antimicrobial drug was found to 
have a signiﬁ  cant (p<0.05) effect in the ﬁ  nal multivariable 
model. Note that we did not adjust for the correlated error 
structure of the data in the ﬁ  nal analysis; because the cor-
relation was low, this adjustment had little effect on our es-
timates (data not shown). The C statistic of the ﬁ  nal model 
was 0.69. Patients categorized on the basis of the presence 
of all of the following dichotomous predictors of the ﬁ  nal 
model (zosyn, vancomycin and age >60) yielded a sensitiv-
ity of 9.4%, speciﬁ  city of 97.3%, positive predictive value 
of 7.3%, and negative predictive value of 97.9%.  
For the 117 patients identiﬁ   ed as colonized with 
ESBL-producing bacteria, we assessed their history of cul-
ture positivity with ESBL-producing bacteria as well as 
other antimicrobial drug–resistant bacteria (Table 3). Of 
the ESBL-colonized patients, 6 (5%) had positive clinical 
cultures for ESBL-producing bacteria during the same hos-
pital admission but before ICU admission, and 29 (25%) 
had a subsequent ESBL-positive clinical culture from the 
time an ICU admission surveillance specimen was obtained 
for culture to the date of hospital discharge. The only risk 
factor that predicted subsequent positive ESBL clinical cul-
ture was the amount of time in the hospital between posi-
tive surveillance culture and hospital discharge (OR 1.03 
per additional day, 95% CI 1.01–1.06). These 29 patients 
had 56 clinical cultures with ESBL-producing bacteria. 
The sources of the 56 clinical cultures positive for ESBL-
producing bacteria were the following: 9 blood cultures, 
17 sputum or bronchoscopy specimens, 10 urine cultures, 
12 wound cultures, and 8 miscellaneous sources. Of 117 
ESBL-colonized patients, 41 (35%) were known to have 
Table 1. Potential predictors of colonization by an ESBL-producing bacterium on ICU admission* 
Potential predictor 
No. ESBL colonized 
(n = 117) 
No. not ESBL colonized 
(n = 5,092)  p value† 
Age, y (median, IQR)  62 (49–71)  56 (45–67)  <0.01
CDS (median, IQR)  8 (5–10)  8 (5–10)  0.20
CDS-ID (median, IQR)  3.21 (1.83–4.78)  2.83 (1.83–3.40)  <0.01
Sex, female, no. (%)  59 (50)  2,311 (45)  0.30
Antimicrobial drug exposures, no. (%)‡ 
  Quinolone  18 (15)  617 (12)  0.32
  1st-generation cephalosporin  9 (8)  559 (11)  0.30
  3rd-generation cephalosporin  7 (6)  293 (6)  0.84
  Vancomycin  34 (29)  616 (12)  <0.01
  Aminoglycoside  11 (9)  366 (7)  0.36
  Piperacillin-tazobactam  50 (43)  1,090 (21)  <0.01
  Cefepime  9 (8)  161 (3)  0.01
  Imipenem  11 (9)  224 (4)  0.02
*ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; IQR, interquartile range; CDS, Chronic Disease Score; CDS-ID, infectious disease–
specific CDS. 
†Fisher exact test for dichotomous predictors and Wilcoxon test for continuous predictors. 
‡Antimicrobial drug exposures that occurred during the index hospital admission but before ICU admission. Colonization with ESBL-producing Bacteria
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been previously infected or colonized with either methicil-
lin-resistant S. aureus (MRSA) or vancomycin-resistant en-
terococci (VRE). Among the 5,092 patients not colonized 
with ESBL-producing bacteria, 33 (0.6%) had a subsequent 
positive ESBL clinical culture with the same bacterial spe-
cies between the time of ICU admission surveillance cul-
ture to the date of hospital discharge.  
Discussion
In this study, we identiﬁ  ed risk factors for coloniza-
tion with ESBL-producing E. coli and Klebsiella spp. at 
ICU admission. We identiﬁ  ed age >60 years, comorbidity 
as measured by the CDS-ID, previous in-hospital piperacil-
lin-tazobactam use (current admission), and previous pres-
ent admission in-hospital vancomycin use (current admis-
sion) as independent risk factors. We also quantiﬁ  ed the 
ESBL colonization/clinical culture positivity rate among 
these patients and addressed the question of whether pa-
tients colonized with ESBL had a history of colonization 
with MRSA and VRE. 
The risk factors identiﬁ  ed are potentially important 
because they can help determine which patients may need 
empiric antimicrobial drug therapy targeted to the ESBL-
producing bacteria. Carbapenem antimicrobial agents 
may be preferred as empiric choice for patients at risk for 
ESBL-producing bacteria (2). We are not recommending 
that all patients with these risk factors receive empiric anti-
microbial drug therapy targeted to ESBL-producing bacte-
ria. However, among particular patients with the identiﬁ  ed 
risk factors and levels of severity of infection that require 
empiric therapy, a choice of empiric therapy that includes 
coverage of ESBL-producing bacteria may be warranted. 
Thus, we recommend that for patients in ICUs with similar 
characteristics to the units in this study, physicians consider 
using antimicrobial agents targeted against ESBL-produc-
ing bacteria. These ESBL-targeted drugs should be consid-
ered when the physician chooses to prescribe an antimicro-
bial drug for situations such as fever of unknown origin, 
suspected pneumonia, or suspected bacteremia. In addition, 
these risk factors identiﬁ  ed may be of use to hospital an-
timicrobial drug stewardship programs and pharmacy and 
therapeutics committees.  
We hope that our risk factor study and other risk factor 
studies in the area of antimicrobial drug resistance will be 
used in future antimicrobial agent stewardship intervention 
studies and future infection control intervention studies. 
Previous risk factor studies have led to antimicrobial agent 
stewardship intervention studies aimed at controlling ESBL-
producing bacteria (14,15). In the areas of pneumonia and 
neutropenia patients with fever, risk factors studies have 
successfully led to intervention studies that have affected 
national guidelines (16–18). Well-designed intervention 
studies, based on risk factor studies of antimicrobial drug 
resistance, can lead to more appropriate antimicrobial drug 
use, which will improve patient outcomes and decrease the 
emergence of antimicrobial drug resistance (19,20).
The risk factors identiﬁ  ed may be causally related to 
the outcome of ESBL-colonization or may only be statisti-
cally associated. Age >60 years and the presence of coex-
isting conditions have validity and biologic plausibility for 
a causal association with colonization status (1,9,21). The 
identiﬁ  cation of piperacillin-tazobactam and vancomycin 
as risk factors is more intriguing. Vancomycin and piper-
acillin-tazobactam are widely used at our tertiary-care hos-
pital, the University of Maryland Medical Center, and thus 
may just be markers of ICU patients who require broad-
spectrum antimicrobial coverage. However, understanding 
intestinal ecology and antimicrobial drug resistance is still 
in nascent stages. Vancomycin and piperacillin-tazobactam 
may be true causal risk factors for colonization with ESBL-
producing bacteria. Piperacillin-tazobactam is believed to 
be effective against ESBL-producing bacteria only when 
the inoculum is low (22). Thus, with regard to the intestinal 
ﬂ  ora, piperacillin-tazobactam may not be effective at eradi-
cating ESBL-producing bacteria due to inoculum effects 
and low intestinal concentration of piperacillin-tazobac-
tam. Additionally, we were surprised by the identiﬁ  cation 
Table 2. Independent predictors of ESBL-producing bacteria 
colonization in multivariable logistic regression model* 
Predictor OR 95% CI
Age >60  1.79 1.24, 2.60 
CDS-ID 1.15 1.04, 1.27
Vancomycin† 2.11 1.34, 3.31
Piperacillin-tazobactam† 2.05 1.36,  3.10 
*ESBL, extended-spectrum β-lactamase; OR, odds ratio; CI, confidence 
interval; CDS-ID, infectious disease–specific Chronic Disease Score. 
†Antimicrobial drug exposures were assessed during the period between 
hospital admission and intensive care unit admission. 
Table 3. History of culture positivity with antimicrobial drug–resistant bacteria among 117 patients colonized with ESBL-producing
bacteria at ICU admission* 
Drug-resistant bacteria  No. ESBL colonized (%) 
ESBL-positive clinical cultures before ICU admission†  6 (5) 
ESBL-positive clinical cultures after colonization  29 (25) 
Methicillin-resistant Staphylococcus aureus† 25 (21)
Vancomycin-resistant enterococci‡  27 (23) 
*ESBL, extended-spectrum β-lactamase; ICU, intensive care unit. 
†Positive clinical cultures during the same hospital admission but before ICU admission. 
‡Clinical or surveillance cultures at any time before ICU admission. RESEARCH
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of piperacillin-tazobactam as a risk factor as some hospi-
tals have adopted antimicrobial drug stewardship policies 
that have limited the prescribing of cephalosporins and 
increased the use of antimicrobial drugs, including piper-
acillin-tazobactam, in an effort to control ESBL-producing 
bacteria (15,23). Vancomycin may be a risk factor through 
relative decolonization of the normal ﬂ  ora through van-
comycin exposure and then subsequent colonization with 
ESBL strains through horizontal transmission before ICU 
admission (24,25).
We found a ratio of colonization to clinical culture 
positivity that was the same order of magnitude as for VRE 
and MRSA (26–29). In addition, only 35% of patients with 
ESBL-colonization were previously known to be VRE or 
MRSA positive. These numbers and the local prevalence 
rate of ESBL-producing bacteria are important parameters 
in assessing the cost-effectiveness of active surveillance for 
ESBL-producing bacteria. Further work, including cost- 
effectiveness studies, needs to address whether active sur-
veillance is beneﬁ  cial for ESBL-producing bacteria.
Several studies. performed worldwide, have analyzed 
risk factors for colonization with multidrug resistant En-
terobacteriaceae. Many studies have not analyzed the spe-
ciﬁ  c antimicrobial drug resistance mechanism and thus are 
not directly comparable to our study. A study from Canada 
determined that several antimicrobial drugs were risk fac-
tors for multidrug resistant Enterobacteriaceae ( 30). In 
contrast to our study, most of their isolates had AmpC as 
a resistance mechanism, and thus their study did not deter-
mine risk factors for ESBL-producing bacteria. A 4-year 
cohort study done in France determined the ESBL-produc-
ing bacteria colonization rate in 2 ICUs to be 0.97% and 
thus concluded that, in their setting, active surveillance was 
unlikely to be cost-effective (31). A study in Israel identi-
ﬁ  ed 26 (10.8%) of 241 patients tested by active surveillance 
as colonized with ESBL-producing bacteria. Risk factors 
identiﬁ  ed in multivariable analysis were poor functional 
status, current antimicrobial drug use, chronic renal insuf-
ﬁ  ciency, liver disease, and the use of histamine2 receptor 
antagonists (32). 
A limitation of our study is that we did not have access 
to records of the antimicrobial drugs that patients may have 
received as outpatients before their hospital admission. 
However, relevant to the question of empiric therapy, most 
intensive care clinicians do not have access to records of 
outpatient antimicrobial drug use when they are empirical-
ly choosing antimicrobial agents. Another limitation of the 
study is that we did not have access to the subsequent ESBL-
positive clinical isolates and thus were unable to compare 
them by molecular epidemiologic methods, such as pulsed-
ﬁ  eld gel electrophoresis, to see whether they were identical 
to the ESBL-colonizing isolates identiﬁ  ed previously. We 
did not perform chart review; thus, the subsequent clinical 
cultures with ESBL-producing bacteria could have repre-
sented either clinical infection or colonization, based on 
deﬁ  nitions from the Centers for Disease Control and Pre-
vention (33). The use of ceftazidime in the screening agar 
may have caused the CTX-M family of β-lactamases to be 
missed. However, no CTX-M enzymes were detected in a 
sample of clinical isolates from the University of Maryland 
Medical School and the adjacent Veterans Affairs Medical 
Center from 2001 to 2002 (34). 
In this study, we identiﬁ  ed risk factors for ESBL-pro-
ducing bacterial colonization among ICU patients. These 
data may be useful for identifying which patients may 
warrant empiric ESBL-targeted antimicrobial drug thera-
py. We also demonstrate that subsequent infections with 
ESBL-producing bacteria develop in a large percentage of 
ICU patients colonized with ESBL-producing bacteria. 
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